Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms

Journal of Immunology

Volumn 174, Issue 12, 2005, Pages 7859-7868

  Wojciechowski, Wojciech ^a   Li, Huifen ^a   Marshall, Shannon ^a   Dell'Agnola, Chiara ^a   Espinoza Delgado, Igor ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CD20 ANTIBODY; CD20 ANTIGEN; DEXAMETHASONE; IMMUNOMODULATING AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C; RITUXIMAB;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE MALIGNANCY; CELL STRAIN; CELL STRAIN DB; CELL STRAIN RAMOS; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; DRUG RESPONSE; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RNA STABILITY; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 20444395865     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.12.7859     Document Type: Article

References (85)

1. Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Lues, B. K. Dallaire, et al. 1997. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
2. Maloney, D. G., T. M. Lues, D. K. Czerwinski, C. Waldichuk, J. Rosenberg, A. Grillo-Lopez, and R. Levy. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466.
3. Berinstein, N. L., A. J. Grillo-Lopez, C. A. White, I. Bence-Bruckler, D. Maloney, M. Czuczman, D. Green, J. Rosenberg, P. McLaughlin, and D. Shen. 1998. Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9: 995-1001.
4. Einfeld, D. A., J. P. Brown, M. A. Valentine, E. A. Clark, and J. A. Ledbetter. 1988. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1: 711-717.
5. 2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121: 1121-1132.
6. Tedder, T. F., and P. Engel. 1994. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today 15: 450-454.
7. Anderson, K. C., M. P. Bates, B. L. Slaughenhoupt, G. S. Pinkus, S. F. Schlossman, and L. M. Nadler. 1984. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63: 1424-1433.
8. Press, O. W., A. G. Fair, K. I. Borroz, S. K. Anderson, and P. J. Martin. 1989. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 49: 4906-4912.
9. Stashenko, P., L. M. Nadler, R. Hardy, and S. F. Schlossman. 1980. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125: 1678-1685.
10. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
11. Reff, M. E., K. Carrier, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
12. Golay, J., M. Lazzari, V. Facchinetti, S. Bernasconi, G. Borleri, T. Barbui, A. Rambaldi, and M. Introna. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98: 3383-3389.
13. Golay, J., L. Zaffaroni, T. Vaccari, M. Lazzari, G. M. Borleri, S. Bernasconi, F. Tedesco, A. Rambaldi, and M. Introna. 2000. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900-3908.
14. Di Gaetano, N., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171: 1581-1587.
15. Harjunpaa, A., S. Junnikkala, and S. Meri. 2000. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51: 634-641.
16. Mathas, S., A. Rickers, K. Bommert, B. Dorken, and M. Y. Mapara. 2000. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 60: 7170-7176.
17. Shan, D., J. A. Ledbetter, and O. W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652.
18. Shan, D., J. A. Ledbetter, and O. W. Press. 2000. Signaling events involved in ami-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48: 673-683.
19. Davis, T. A., D. K. Czerwinski, and R. Levy. 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5: 611-615.
20. Almasri, N. M., R. E. Duque, J. Iturraspe, E. Everett, and R. C. Braylan. 1992. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocyte leukemia. Am. J. Hematol. 40: 259-263.
21. Mutter, R., and M. Wills. 2000. Chemistry and clinical biology of the bryostatins. Bioorg. Med. Chem. 8: 1841-1860.
22. Stone, R. M., E. Sariban, G. R. Pettit, and D. W. Kufe. 1988. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 72: 208-213.
23. Hornung, R. L., J. W. Pearson, M. Beckwith, and D. L. Longo. 1992. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 52: 101-107.
24. Jones, R. J., S. J. Sharkis, C. B. Miller, E. K. Rowinsky, P. J. Burke, and W. S. May. 1990. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 75: 1319-1323.
25. Berkow, R. L., and A. S. Kraft. 1985. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem. Biophys. Rex. Commun. 131: 1109-1116.
26. Berkow, R. L., L. Schlabach, R. Dodson, W. H. Benjamin, Jr., G. R. Pettit, P. Rustagi, and A. S. Kraft. 1993. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. 53: 2810-2815.
27. Drexler, H. G., S. M. Gignac, G. R. Pettit, and A. V. Hoffbrand. 1990. Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation. Eur. J. Immunol. 20: 119-127.
28. Scheid, C., J. Prendiville, G. Jayson, D. Crowther, B. Fox, G. R. Pettit, and P. L. Stern. 1994. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase 1 clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol. Immunother. 39: 223-230.
29. Taylor, L. S., G. W. Cox, G. Melillo, M. C. Bosco, and I. Espinoza-Delgado. 1997. Bryostatin-1 and IFN-γ synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages. Cancer Res. 57: 2468-2473.
30. Philip, P. A., D. Rea, P. Thavasu, J. Carmichael, N. S. Stuart, H. Rockett, D. C. Talbot, T. Ganesan, G. R. Pettit, F. Balkwill, et al. 1993. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor a induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. 85: 1812-1818.
31. Bosco, M. C., S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado. 1997. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: synergy with interleukin-2 and modulation of interleukin-2Rγ chain expression. Blood 89: 3402-3411.
32. Curiel, R. E., C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado. 2001. Bryostatin-1 and IL-2 synergize to induce IFN-γ expression in human peripheral blood T cells: implications for cancer immunotherapy. J. Immunol. 167: 4828-4837.
33. Correa, M. R., A. C. Ochoa, P. Ghosh, H. Mizoguchi, L. Harvey, and D. L. Longo. 1997. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol. 158: 5292-5296.
34. Wang, Q., J. Stanley, S. Kudoh, J. Myles, V. Kolenko, T. Yi, R. Tubbs, R. Bukowski, and J. Finke. 1995. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. 155: 1382-1392.
35. Scrivener, S., R. V. Goddard, E. R. Kaminski, and A. G. Prentice. 2003. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 44: 383-389.
36. + T-cell subset in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 104: 589-599.
37. + T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br. J. Haematol. 112: 760-770.
38. Beckwith, M., W. J. Urba, and D. L. Longo. 1993. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J. Natl. Cancer Inst. 85: 483-488.
39. 2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol. Immunother. 51: 15-24.
40. Klein, G., B. Giovanella, A. Westman, J. S. Stehlin, and D. Mumford. 1975. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics: EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5: 319-334.
41. Curiel, R. E., C. S. Garcia, S. Rottschafer, M. C. Bosco, and I. Espinoza-Delgado. 1999. Enhanced B7-2 gene expression by interferon-γ in human monocytic cells is controlled through transcriptional and posttranscriptional mechanisms. Blood 94: 1782-1789.
42. Wang, X., Q. Wang, W. Hu, and B. M. Evers. 2004, Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-κB-dependent pathway. Oncogene 23: 1885-1895.
43. Liu, W., N. Reinmuth, O. Stoeltzing, A. A. Parikh, C. Tellez, S. Williams, Y. D. Jung, F. Fan, A. Takeda, M. Akagi, et al. 2003. Cyclooxygenase-2 is up-regulated by interleukin-1β in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 63: 3632-3636.
44. Auphan, N., J. A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270: 286-290.
45. De Bosscher, K., W. Vanden Berghe, and G. Haegeman. 2000. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109: 16-22.
46. Duncia, J. V., J. B. Santella III, C. A. Higley, W. J. Pitts, J. Wityak, W. E. Frietze, F. W. Rankin, J. H. Sun, R. A. Earl, A. C. Tabaka, et al. 1998. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8: 2839-2844.
47. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270: 27489-27494.
48. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273: 18623-18632.
49. + T cell adhesion to B cells. Cell. Immunol. 150: 439-446.
50. Rastetter, W., A. Molina, and C. A. White. 2004. Rituximab: expanding role in therapy for iymphomas and autoimmune diseases. Annu. Rev. Med. 55: 477-503.
51. Davis, T. A., A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy. 2000. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18: 3135-3143.
52. Davis, T. A., C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin. Oncol. 17: 1851-1857.
53. Piro, L. D., C. A. White, A. J. Grillo-Lopez, N. Janakiraman, A. Saven, T. M. Beck, C. Varns, S. Shuey, M. Czuczman, J. W. Lynch, et al. 1999. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10: 655-661.
54. Nguyen, D. T., J. A. Amess, H. Doughty, L. Hendry, and L. W. Diamond. 1999. 1DEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol. 62: 76-82.
55. Venugopal, P., S. Sivaraman, X. K. Huang, J. Nayini, S. A. Gregory, and H. D. Preisler. 2000. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk. Res. 24: 411-415.
56. Sivaraman, S., C. G. Deshpande, R. Ranganathan, X. Huang, A. Jajeh, T. O'Brien, R. W. Huang, S. A. Gregory, P. Venugopal, and H. D. Preisler. 2000. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNFα? Microsc. Res. Tech. 50: 251-257.
57. Sivaraman, S., P. Venugopal, R. Ranganathan, C. G. Deshpande, X. Huang, A. Jajeh, S. A. Gregory, T. O'Brien, and H. D. Preisler. 2000. Effect of interferon-α on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol. Ther. 6: 81-87.
58. Treon, S. P., L. M. Pilarski, A. R. Belch, A. Kelliher, F. I. Preffer, Y. Shima, C. S. Mitsiades, N. S. Mitsiades, A. J. Szczepek, L. Ellman, et al. 2002. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J. Immunother. 25: 72-81.
59. Battle, T. E., and D. A. Frank. 2003. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood 102: 3016-3024.
60. Lilly, M., K. Vo, T. Le, and G. Takahashi. 1996. Bryostatin 1 acts synergistically with interleukin-1α to induce secretion of G-CSF and other cytokines from marrow stromal cells. Exp. Hematol. 24: 613-621.
61. Tedder, T. F., G. Klejman, S. F. Schlossman, and H. Saito. 1989. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J. Immunol. 142: 2560-2568.
62. Thevenin, C., B. P. Lucas, E. J. Kozlow, and J. H. Kehrl. 1993. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J. Biol. Chem. 268: 5949-5956.
63. Himmelmann, A., A. Riva, G. L. Wilson, B. P. Lucas, C. Thevenin, and J. H. Kehrl. 1997. PU, 1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. Blood 90: 3984-3995.
64. Dittmer, J. 2003. The biology of the Ets1 proto-oncogene. Mol. Cancer 2: 29.
65. Lin, H., C. Chen, X. Li, and B. D. Chen. 2002. Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differentiation and upregulation of X-linked inhibitor of apoptosis protein. Exp. Cell Res. 272: 192-198.
66. Vrana, J. A., and S. Grant. 2001. Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade. Blood 97: 2105-2114.
67. Kraft, A. S., J. A. Reeves, and C. L. Ashendel, 1988. Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells. J. Biol Chem. 263: 8437-8442.
68. Hennings, H., P. M. Blumberg, G. R. Pettit, C. L. Herald, R. Shores, and S. H. Yuspa. 1987. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 8: 1343-1346.
69. Ramsdell, J. S., G. R. Pettit, and A. H. Tashjian, Jr. 1986. Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells. J. Biol. Chem. 261: 17073-17080.
70. Wang, H., R. M. Mohammad, J. Werdell, and P. V. Shekhar. 1998. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Int. J. Mol. Med. 1: 915-923.
71. Spitaler, M., I. Utz, W. Hilbe, J. Hofmann, and H. H. Grunicke. 1998. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem. Phannacol. 56: 861-869.
72. Szallasi, Z., L. Du, R. Levine, N. E. Lewin, P. N. Nguyen, M. D. Williams, G. R. Pettit, and P. M. Blumberg. 1996. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res. 56: 2105-2111.
73. Yang, C., and M. G. Kazanietz, 2003. Divergence and complexities in DAG signaling: looking beyond PKC. Trends Pharmacol. Sci. 24: 602-608.
74. Wall, N. R., R. M. Mohammad, and A. M. Al-Katib. 2001. Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh. Cell Growth Differ. 12: 641-647.
75. Toullec, D., P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, et al. 1991. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266: 15771-15781.
76. Birkenkamp, K. U., L. M. Tuyt, C. Lummen, A. T. Wierenga, W. Kruijer, and E. Vellenga. 2000. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-κB transcriptional activity by a non-specific effect upon the ERK pathway. Br. J. Pharmacol. 131: 99-107.
77. Rahmsdorf, H. J., N. Harth, A. M. Eades, M. Litfin, M. Steinmetz, L. Forni, and P. Herrlich. 1986. Interferon-γ, mitomycin C. and cycloheximide as regulatory agents of MHC class II-associated invariant chain expression. J. Immunol. 136: 2293-2299.
78. Maffei, A., C. Perfetto, N. Ombra, G. Del Pozzo, and J. Guardiola. 1989. Transcriptional and post-transcriptional regulation of human MHC class II genes require the synthesis of short-lived proteins. J. Immunol. 142: 3657-3661.
79. Stordeur, P., L. Schandene, P. Durez, C. Gerard, M. Goldman, and T. Velu. 1995. Spontaneous and cycloheximide-induced interleukin-10 mRNA expression in human mononuclear cells. Mol. Immunol. 32: 233-239.
80. Bertoglio, J., J. Dosda, R. Stancou, E. Wollman, and D. Fradelizi. 1989. Expression and regulation of interleukin-1 mRNA and interleukin-1 receptors in human B-cell lines. J. Mol. Cell. Immunol. 4: 139-148.
81. Scheinman, R. I., P. C. Cogsweli, A. K. Lofquist, and A. S. Baldwin, Jr, 1995. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270: 283-286.
82. Rose, A. L., B. E. Smith, and D. G. Maloney. 2002. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 100: 1765-1773.
83. Treon, S. P., C. Mitsiades, N. Mitsiades, G. Young, D. Doss, R. Schlossman, and K. C. Anderson. 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunother. 24: 263-271.
84. Trenn, G., G. R. Pettit, H. Takayama, J. Hu-Li, and M. V. Sitkovsky. 1988. Immunomodulating properties of a novel seiies of protein kinase C activators: the bryostatins. J. Immunol. 140: 433-439.
85. Jayson, G. C., D. Crowther, J. Prendiville, A. T. McGown, C. Scheid, P. Stern, R. Young, P. Brenchley, J. Chang, S. Owens, et al. 1995. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer 72: 461-468.